EUVIMEDEUVIMED entdecken
Crossref

Lack of Interactions Between Alteplase/Tenecteplase and the Adenosine A1R/A3R Agonist AST-004

Theodore E Liston iD, Deborah Holstein, Derek Solt, Damian Lozano iD, William S Korinek iD, James D Lechleiter iD

Stroke · 2024

DOI: 10.1161/strokeaha.124.046688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2024. Verfasst von Theodore E Liston und 5 weiteren Autor:innen. Beteiligte Einrichtung: Astrocyte Pharmaceuticals Inc, Groton, CT (T.E.L., W.S.K.). Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Tenecteplase, Fibrinolytic Agents, Drug Interactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: AST-004, a small molecule agonist of the adenosine A1 and A3 receptors, is a potential cerebroprotectant for patients with acute stroke and is currently in clinical trials. Drug-drug interactions are critically important to assess in the context of acute stroke care. Lytic therapy with tPA (tissue-type plasminogen activator)–induced plasmin formation (alteplase) is the only available pharmacotherapy for acute stroke. Consequently, it is imperative to evaluate potential interactions between AST-004 and tPAs such as alteplase and tenecteplase. METHODS: The interactions between AST-004 and tPAs were evaluated in 3 ways in preparation for AST-004 phase II trials. First, the metabolic stability of AST-004 was determined in the presence of alteplase and plasmin. Second, the potential for AST-004 to influence the thrombolytic efficacy of alteplase and tenecteplase was evaluated with an in vitro assay system utilizing a fluorogenic substrate of plasmin. Finally, the potential for AST-004 to influence the thrombolytic efficacy of alteplase was also determined with an in vitro thrombolysis assay of human blood thrombi. RESULTS: Neither alteplase nor plasmin affected the stability of AST-004 in vitro. In 2 different in vitro systems, AST-004 had no effect on the ability of alteplase or tenecteplase to generate plasmin, and AST-004 had no effect on the thrombolytic efficacy of alteplase to lyse blood clots in human blood. CONCLUSIONS: These studies indicate that there will be no interactions between AST-004 and tPAs such as alteplase or tenecteplase in patients with stroke undergoing thrombolytic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Plasminogen ActivatorTenecteplaseFibrinolytic AgentsDrug InteractionsHumansAdenosine A1 Receptor AgonistsReceptor, Adenosine A3FibrinolysinStrokeReceptor, Adenosine A1

Stichwörter der Autor:innen

drug interactionsstroketenecteplasethrombolytic therapytissue-type plasminogen activator

Substanzen

Tissue Plasminogen ActivatorTenecteplaseFibrinolytic AgentsAdenosine A1 Receptor AgonistsReceptor, Adenosine A3FibrinolysinReceptor, Adenosine A1

Autor:innen und Institutionen

  • Astrocyte Pharmaceuticals Inc, Groton, CT (T.E.L., W.S.K.).
  • Department of Cell Systems and Anatomy, University of Texas Health San Antonio (D.H., D.L., J.D.L.).
  • Thrombodyne MDEC, LLC, Salt Lake City, UT (D.S.).

ORCID-Profile: Theodore E Liston, Damian Lozano, William S Korinek, James D Lechleiter

Zitieren

APA

Liston, T. E., Holstein, D., Solt, D., Lozano, D., Korinek, W. S., & Lechleiter, J. D. (2024). Lack of Interactions Between Alteplase/Tenecteplase and the Adenosine A1R/A3R Agonist AST-004. Stroke. https://doi.org/10.1161/strokeaha.124.046688

Vancouver

Liston TE, Holstein D, Solt D, Lozano D, Korinek WS, Lechleiter JD. Lack of Interactions Between Alteplase/Tenecteplase and the Adenosine A1R/A3R Agonist AST-004. Stroke. 2024. doi:10.1161/strokeaha.124.046688

BibTeX
@article{Liston2024,
  author = {Liston, Theodore E and Holstein, Deborah and Solt, Derek and Lozano, Damian and Korinek, William S and Lechleiter, James D},
  title = {Lack of Interactions Between Alteplase/Tenecteplase and the Adenosine A1R/A3R Agonist AST-004},
  journal = {Stroke},
  year = {2024},
  doi = {10.1161/strokeaha.124.046688}
}
Kostenlos starten →